 | |
| Clinical data | |
|---|---|
| Other names | Epistane; Hemapolin; Havoc; Epi Plex; Methylepithiostanol; Methepitiostane; 17α-Methylepitiostanol; 2α,3α-Epithio-17α-methyl-4,5α-dihydrotestosterone; 2α,3α-Epithio-17α-methyl-DHT |
| Routes of administration | By mouth[1] |
| Drug class | Androgen;Anabolic steroid;Antiestrogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H32OS |
| Molar mass | 320.54 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methylepitiostanol, known by the nicknamesEpistane,Hemapolin,Havoc, andEpi Plex, is asynthetic andorally activeanabolic–androgenic steroid (AAS) of thedihydrotestosterone (DHT) group which was first described in the literature in 1974 but was never marketed for medical use.[1][2][3] It is the17α-methylated derivative ofepitiostanol, an AAS andantiestrogen which was formerly used in the treatment ofbreast cancer inJapan.[1][2] Similarly tomepitiostane, methylepitiostanol is an orally active variant of epitiostanol.[1][2] Due to its C17α methyl group, the drug is considered to have a high potential forhepatotoxicity.[1]
Methylepitiostanol surfaced on the internet as a noveldesigner steroid indietary supplements around 2009.[1] It was identified in 2015 in over 30 products sold online that listed it as an ingredient on their product label.[1]
It became a controlled substance in the United States in 2014 with the passage of the Designer Anabolic Steroid Control Act, which explicitly listed it among 27 new steroids as controlled by the Act.
Methylepitiostanol, also known as 2α,3α-epithio-17α-methyl-4,5α-dihydrotestosterone (2α,3α-epithio-17α-methyl-DHT) or as 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol, is asyntheticandrostanesteroid and a17α-alkylatedderivative of DHT.[1][2] It is closely related to epitiostanol (2α,3α-epithio-DHT) and mepitiostane (epitiostanol 17-methyloxycyclopentyl ether).[1]